Ocuphire Pharma(OCUP) - 2023 Q2 - Quarterly Report

Washington, DC 20549 Form 10-Q (Mark One) UNITED STATES SECURITIES AND EXCHANGE COMMISSION ☒ QUARTERLY REPORT PURSUANT TO SECTION 13 OR 15(d) OF THE SECURITIES EXCHANGE ACT OF 1934 For the Quarterly Period Ended June 30, 2023 OR ☐ TRANSITION REPORT PURSUANT TO SECTION 13 OR 15(d) OF SECURITIES EXCHANGE ACT OF 1934 For the transition period from to ________ Commission File Number: 001-34079 Ocuphire Pharma, Inc. (Exact name of Registrant as specified in its charter) Delaware 11-3516358 (State or Other Jurisd ...